Search results
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With over 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive ...
- Products & Services
Bachem was founded on the synthesis of amino acid...
- About Bachem
Bachem is a leading, innovation-driven company specializing...
- News & Events
As Bachem is the world’s leading company in developing and...
- Knowledge Center
Bachem provides a wide range of documentation and practical...
- Careers
Bachem is committed to working with and providing reasonable...
- Contact
Bachem AG Hauptstrasse 144 4416 Bubendorf Switzerland. Tel...
- CMC Development
Certainly, Bachem's expertise in peptides, their...
- Commercial API
You come first – We pride ourselves on a consistently high...
- Products & Services
Bachem Holding AG is a Swiss bio-technology company active in the fields of chemistry, biochemistry and pharmaceuticals.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a ...
Get the latest BACHEM HOLDING AG (BANB) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Find the latest Bachem Holding AG (BANB.SW) stock quote, history, news and other vital information to help you with your stock trading and investing.
Access past financial reports, download company presentations and watch the replay of our last media and analyst conference.
BACHEM AT THE CPHI TRADE FAIR IN BARCELONA Bachem presents solutions for scalable oligonucle-otide production and oligonucleotide quality control. JULY 27 SLIGHT SALES GROWTH IN THE FIRST HALF OF 2023 Group sales increase to CHF 239.9˜million (+2.1%, +5.3% in local currencies). EBITDA margin of 21.9%. JUNE 24 BACHEM AT THE AMERICAN PEPTIDE